Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Rheumatoid Arthritis
In brief
The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.
Key facts
- Study ID
- NCT03417778
- Run by
- Gilead Sciences
- People needed
- 20
- Starts
- 2018-04-03
- Expected to finish
- 2018-08-09
- Last updated by the study team
- 2021-01-15
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami — Miami, Florida, United States
- American Research Corporation at the Texas Liver Institute — San Antonio, Texas, United States
- APEX GmbH — Munich, Germany
- Auckland Clinical Studies Ltd. — Grafton, Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.